GHK-Cu: what the copper peptide does in skin, and what the evidence does not support
A copper-bound tripeptide that skin releases when damaged. What has been measured in collagen and elastin, what has only been seen in cells and animals, and what cannot be promised.
GHK-Cu is three amino acids —glycine, histidine and lysine— bound to a copper ion. The sequence sits inside the alpha 2(I) chain of type I collagen, circulates in human plasma, and skin releases it when it is damaged. It is the active ingredient Nectalis prescribes as a cream within its skin care and dermal regeneration protocol. Collagen and elastin have measurements behind them, from fibroblast cultures and small clinical trials; almost everything else has cells and mice behind it. This article separates the two.
Where this molecule comes from
The GHK tripeptide was identified in human plasma in 1973. An experiment from that period already anticipated what was coming: plasma from young people, added to liver tissue from older people, made that tissue produce proteins more typical of a young organism.
Its plasma concentration depends on age. Around age 20 it sits near 200 ng/mL; by 60 it falls to about 80 ng/mL. That decline is what supports the idea that the molecule takes part in repair: if it drops with age, skin loses part of a signal it used to have.
That is why a three-amino-acid tripeptide is the active ingredient Nectalis prescribes as a cream within its skin care protocol. What follows is the evidence behind that use, and also its edges.
In the 1980s, Maquart and colleagues proposed that GHK is an early repair signal. The argument has a structural basis: because the GHK sequence sits inside the collagen molecule, when an injury activates the enzymes that break down proteins, the tripeptide is released right at the site of damage.
The 2010 turn: gene expression data
The change in explanation arrived with a tool from the Broad Institute (MIT and Harvard), the Connectivity Map — a public library of transcriptional responses to known compounds. It made it possible to look at which genes GHK changes across the whole genome, instead of hunting for a single mechanism.
The analysis found that GHK changes the expression of 31.2% of human genes by at least 50%, increasing it in 59% of cases and decreasing it in 41%. The breakdown by range:
| Change in expression | Genes stimulated | Genes suppressed |
|---|---|---|
| 50–99% | 1569 | 583 |
| 100–199% | 646 | 469 |
| 200–299% | 227 | 196 |
| 300–599% | 196 | 207 |
| 600–899% | 39 | 47 |
| 900–1199% | 8 | 7 |
| 1200% or more | 2 | 4 |
Half a dozen genes move by more than 1200%. That explains why a single tripeptide turns up in such different processes, and it also marks the limit of the interpretation: a gene expression profile says what changed, not what caused what. The authors write it themselves — they consider the model of action in need of revision, and expect it to require collaboration across fields.
And it is worth reading this paper knowing who signed it. Both authors discovered the peptide and hold patents on its use (the article lists one of them as reference 41). It is a review by interested parties, not an independent one. The data are traceable and the citations verifiable, but the interpretive frame is written by the people who have worked with the molecule for four decades.
What has actually been measured in skin
In fibroblast cultures — the cells that build the dermal matrix. GHK stimulates the synthesis of collagen, of sulfated glycosaminoglycans and of the proteoglycan decorin. It also modulates metalloproteinases, the enzymes that break down the extracellular matrix, and their inhibitors. That dual effect matters: if only degradation were activated, the matrix would weaken; if only blocked, damaged proteins would accumulate. Maquart's group published these measurements in 1992 and 2000.
In keratinocytes — the cells of the epidermis. The copper complex increased the expression of integrins and p63, and the cells took on a more cuboidal shape, an indicator of greater stem-cell character. Kang and colleagues reported this in 2009.
And before going further: this is a topically applied peptide, which is what skin needs here. If you are interested in why the route of administration completely changes what a peptide can do, it is set out in injectable and oral peptides.
In clinical trials, with the caution they require. A facial cream with GHK-Cu applied for 12 weeks to 71 women with mild to advanced photodamage increased skin density and thickness, reduced laxity, improved clarity, and reduced fine lines and wrinkle depth. That data was presented at the American Academy of Dermatology annual meeting in 2002, and this matters: it is a conference abstract, not a peer-reviewed paper, and the data set cannot be consulted.
There is a 2016 randomised, double-blind trial comparing GHK-Cu encapsulated in a nano-lipid carrier with a control and with another cosmetic peptide over 8 weeks. Against the reference peptide, wrinkle volume fell 31.6%; against the control serum, 55.8%, with depth down 32.8%. That trial was published in a low-impact journal, so the figure reads as a signal, not as a benchmark for comparing products.
And the prior question: does it reach the dermis? GHK-Cu crosses the stratum corneum in in vitro models, which is the condition for a cosmetic to do anything beyond sitting on the surface. Howard Maibach's laboratory measured it in 2010.
What this peptide also does in the lab, and here you will not read as a benefit
The review devotes several sections to results against diseases: anti-tumour activity in cell lines and mice, reversal of the emphysema gene signature in lung fibroblasts from COPD patients, and anxiolytic and analgesic effects measured in rats at microgram-per-kilogram doses.
They are real results in the sense that they are published, and they are exactly the kind of data a brand turns into a headline. We will not, for two concrete reasons:
- They are claims about diseases, made in cells and animals. Turning them into a product benefit would jump from a model to a promise the studies themselves do not support.
- The product prescribed is a facial cream. Its indication is cosmetic and superficially dermatological; COPD or a tumour are not part of it, and saying otherwise would be promoting an unauthorised use.
Naming them here is the honest part. Selling them is what cannot be done.
Formulation: why the vehicle matters
GHK is sensitive to carboxypeptidases, enzymes that cut the end off the chain and inactivate it. That fragility explains why the literature insists on the vehicle: liposomes — including nanometre-scale ones — and delivery systems improve its penetration. The review also proposes it after invasive cosmetic procedures, where the skin barrier is compromised.
One piece of context that is data: the copper in this tripeptide is not decoration. It is a cofactor for a dozen human enzymes, including lysyl oxidase, which takes part in collagen cross-linking. That is why collagen synthesis depends on copper, and why there is a natural dietary limit to that route: the cacao and tahini elixir covers close to 86% of the reference daily intake of copper with no supplements.
Frequently asked questions
How long before a change is visible?
We publish no timelines, because we cannot hold them up. The trials cited here applied the product for 8 and 12 weeks and measured average changes in groups of dozens of women; they do not say how much changes in one person, or how quickly. In reference clinical trials, results are reported as a group average, and individual response varies.
Can I combine it with retinol, acids or vitamin C?
The review does not study combinations, so we claim neither compatibility nor incompatibility. Any application schedule, and all the more if you are following another dermatological treatment, is a matter for the professional evaluating you.
Is it the same as taking collagen?
No. Oral hydrolysed collagen is a protein supplement and is studied on its own terms. GHK-Cu is a three-amino-acid tripeptide bound to a copper ion, formulated for application to the skin. Different molecules, different routes, different questions.
Are GHK and GHK-Cu the same thing?
Almost. GHK is the tripeptide; GHK-Cu is the complex it forms with copper(II). The difference is not small: part of the published effects are attributed to the molecule's ability to carry copper into the cell.
Do I need a prescription for a copper peptide?
The Nectalis protocol is compounded at a state-licensed 503A pharmacy and dispensed only on an individualised prescription, after a prior clinical evaluation. Nectalis does not sell medicines directly on this website: what patients engage is the evaluation and the ongoing follow-up. You can see how the skin care protocol works. If you are coming from reading about peptides in general, the useful starting point is what a peptide can and cannot do.
Sources
- Pickart, L.; Margolina, A. *Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data*. Int. J. Mol. Sci. 2018, 19(7), 1987. DOI `10.3390/ijms19071987`. Open access (CC BY). Verified via Crossref on 2026-10-05.
- Maquart, F. X. et al. *Stimulation of sulfated glycosaminoglycan synthesis by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+*. Life Sci. 1992. DOI `10.1016/0024-3205(92)90504-i`.
- Maquart, F. X. et al. *The tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures*. Life Sci. 2000. DOI `10.1016/s0024-3205(00)00803-1`.
- Kang, Y. A. et al. *Copper-GHK increases integrin expression and p63 positivity by keratinocytes*. Arch. Dermatol. Res. 2009. DOI `10.1007/s00403-009-0942-x`.
- Badenhorst, T. et al. *Effects of GHK-Cu on MMP and TIMP Expression, Collagen and Elastin Production, and Facial Wrinkle Parameters*. J. Aging Sci. 2016. DOI `10.4172/2329-8847.1000166`.
- Hostynek, J. J.; Dreher, F.; Maibach, H. I. *Human skin retention and penetration of a copper tripeptide in vitro as function of skin layer*. Inflamm. Res. 2010. DOI `10.1007/s00011-010-0214-4`.
- Campbell, J. D. et al. *A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK*. Genome Med. 2012. DOI `10.1186/gm367`. Cited here as the origin of the lung finding that is not used as a benefit.
Medical Disclaimer: *The information provided in this article is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. Always consult your physician before making any changes to your medication or lifestyle regimen.*
Interested in personalized medical protocols?
Explore our compounded GLP-1, 503A Peptides, and hormone optimization options.